22nd Century EBITDA Margin 2011-2024 | XXII
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for 22nd Century (XXII) over the last 10 years. The current EBITDA margin for 22nd Century as of September 30, 2024 is .
| 22nd Century EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$0.03B |
$-0.02B |
-85.19% |
| 2024-06-30 |
$0.03B |
$-0.03B |
-93.10% |
| 2024-03-31 |
$0.03B |
$-0.04B |
-124.14% |
| 2023-12-31 |
$0.03B |
$-0.04B |
-128.13% |
| 2023-09-30 |
$0.02B |
$-0.03B |
-113.04% |
| 2023-06-30 |
$0.03B |
$-0.03B |
-97.06% |
| 2023-03-31 |
$0.04B |
$-0.03B |
-77.50% |
| 2022-12-31 |
$0.04B |
$-0.03B |
-75.00% |
| 2022-09-30 |
$0.05B |
$-0.04B |
-80.00% |
| 2022-06-30 |
$0.04B |
$-0.03B |
-84.62% |
| 2022-03-31 |
$0.03B |
$-0.03B |
-90.91% |
| 2021-12-31 |
$0.03B |
$-0.03B |
-87.10% |
| 2021-09-30 |
$0.03B |
$-0.02B |
-80.00% |
| 2021-06-30 |
$0.03B |
$-0.02B |
-72.41% |
| 2021-03-31 |
$0.03B |
$-0.02B |
-70.37% |
| 2020-12-31 |
$0.03B |
$-0.02B |
-66.67% |
| 2020-09-30 |
$0.03B |
$-0.02B |
-62.96% |
| 2020-06-30 |
$0.03B |
$-0.02B |
-76.92% |
| 2020-03-31 |
$0.03B |
$-0.02B |
-80.77% |
| 2019-12-31 |
$0.03B |
$-0.02B |
-88.00% |
| 2019-09-30 |
$0.03B |
$-0.02B |
-88.00% |
| 2019-06-30 |
$0.03B |
$-0.02B |
-84.00% |
| 2019-03-31 |
$0.03B |
$-0.02B |
-88.46% |
| 2018-12-31 |
$0.03B |
$-0.02B |
-88.46% |
| 2018-09-30 |
$0.03B |
$-0.02B |
-88.00% |
| 2018-06-30 |
$0.02B |
$-0.02B |
-79.17% |
| 2018-03-31 |
$0.02B |
$-0.02B |
-71.43% |
| 2017-12-31 |
$0.02B |
$-0.01B |
-76.47% |
| 2017-09-30 |
$0.01B |
$-0.01B |
-85.71% |
| 2017-06-30 |
$0.01B |
$-0.01B |
-91.67% |
| 2017-03-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2016-12-31 |
$0.01B |
$-0.01B |
-91.67% |
| 2016-09-30 |
$0.01B |
$-0.01B |
-91.67% |
| 2016-06-30 |
$0.01B |
$-0.01B |
-100.00% |
| 2016-03-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2015-12-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2015-09-30 |
$0.01B |
$-0.02B |
-250.00% |
| 2015-06-30 |
$0.00B |
$-0.02B |
-500.00% |
| 2015-03-31 |
$0.00B |
$-0.02B |
-1500.00% |
| 2014-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-09-30 |
$0.01B |
0 |
0.00% |
| 2014-06-30 |
$0.01B |
$0.00B |
28.57% |
| 2013-09-30 |
$0.00B |
$-0.00B |
inf% |
| 2012-09-30 |
$0.00B |
$-0.00B |
inf% |
| 2011-12-31 |
$0.00B |
$-0.00B |
-400.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.005B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
